Saturday 17 October 2026
Export VAXX’s income statement to Excel — free account
Vaxxinity, Inc.
VAXX Healthcare Biotechnology
0.00
0.00
NaN
Follow VAXX
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(94.94%) | (108.96%) | (126.96%) | (150.65%) | |
| (64.69%) | (69.21%) | (73.15%) | (75.55%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(127.62%) | (151.52%) | (183.75%) | (213.19%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.46) | (0.47) | (0.48) | (0.46) | |
Free Cash Flow |
(57.79) | (58.96) | (60.55) | (58.04) | |
Capital Expenditures |
(1.32) | (0.88) | (0.68) | (0.80) | |
| Other line items | |||||
Cash ROIC |
(45.68%) | (57.02%) | (77.23%) | (101.52%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.87 | 1.86 | 0.74 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
566.68 | 333.63 | 468.30 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(63.75) | (57.50) | (44.18) | (83.74) | |
Operating CF/Net income |
0.75 | 0.81 | 0.91 | 1.01 | |
Depreciation/Fixed assets |
0.05 | 0.02 | 0.05 | 0.07 | |
Capex/Depreciation |
(2.36) | (3.83) | (1.24) | (1.10) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.46) | (0.47) | (0.45) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates